- 2 次围观
产品图片
货号/SKU
NR-55439
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、3
产品描述信息
NR-55439??SARS-Related Coronavirus 2, Isolate USA/CA/VRLC012/2021 (Lineage P.2; Zeta Variant)(Viruses)|SARS-Related Coronavirus 2|Isolate USA/CA/VRLC012/2021 (Lineage P.2; Zeta Variant)|-60°C or colder|AS PekoszAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA/CA/VRLC012/2021 (Lineage P.2; Zeta Variant), NR-55439, contributed by Andrew S. Pekosz.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate USA/CA/VRLC012/2021 (also referred to as USA/CA-Stanford-04_S01/2021) was isolated from a mid-turbinate nasal swab from an adult on January 23, 2021 in California, USA.
Note: Genome sequence information is provided on the Certificate of Analysis and includes an analysis of all sequence variations observed for each lot.
Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate USA/CA/VRLC012/2021 is assigned lineage P.2 (sub-lineage of B.1.1.28) and GISAID clade GR using Phylogenetic Assignment of Named Global Outbreak LINeages (PANGOLIN) tool. The complete genome of SARS-CoV-2, isolate USA/CA/VRLC012/2021 has been sequenced (GISAID: EPI_ISL_1364506). The following mutations are present in the clinical isolate (referred to as hCoV-19/USA/CA-Stanford-04_S01/2021): Spike D614G, Spike E484K, Spike V1176F, N (Nucleocapsid protein) G204R, N M234I, N R203K, NSP3 (Non-structural protein 3) P992L, NSP3 V253A, NSP7 (Non-structural protein 7) L71F, NSP12 (Non-structural protein 12) P323L. SARS-CoV-2, lineage P.2 was first detected in Brazil and labelled as a variant of interest (VOI). It was labelled as Zeta variant by the World Health Organization (WHO).
Each vial contains approximately 0.1 mL of spin-clarified cell lysate and supernatant from Homo sapiens lung adenocarcinoma epithelial cells (Calu-3) infected with SARS-CoV-2, isolate USA/CA/VRLC012/2021.
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate USA/CA/VRLC012/2021 (also referred to as USA/CA-Stanford-04_S01/2021) was isolated from a mid-turbinate nasal swab from an adult on January 23, 2021 in California, USA.
Note: Genome sequence information is provided on the Certificate of Analysis and includes an analysis of all sequence variations observed for each lot.
Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate USA/CA/VRLC012/2021 is assigned lineage P.2 (sub-lineage of B.1.1.28) and GISAID clade GR using Phylogenetic Assignment of Named Global Outbreak LINeages (PANGOLIN) tool. The complete genome of SARS-CoV-2, isolate USA/CA/VRLC012/2021 has been sequenced (GISAID: EPI_ISL_1364506). The following mutations are present in the clinical isolate (referred to as hCoV-19/USA/CA-Stanford-04_S01/2021): Spike D614G, Spike E484K, Spike V1176F, N (Nucleocapsid protein) G204R, N M234I, N R203K, NSP3 (Non-structural protein 3) P992L, NSP3 V253A, NSP7 (Non-structural protein 7) L71F, NSP12 (Non-structural protein 12) P323L. SARS-CoV-2, lineage P.2 was first detected in Brazil and labelled as a variant of interest (VOI). It was labelled as Zeta variant by the World Health Organization (WHO).
Each vial contains approximately 0.1 mL of spin-clarified cell lysate and supernatant from Homo sapiens lung adenocarcinoma epithelial cells (Calu-3) infected with SARS-CoV-2, isolate USA/CA/VRLC012/2021.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
与中间鼻甲鼻拭子分离出分离急性急性呼吸综合征相关的冠状病毒2（SARS-COV-2），分离为USA / CA / VRLC012 / 2021（也称为USA / CA-STANFORD-04_S01 / 2021）成人在2021年1月23日在加利福尼亚，美国.
注意：基因组序列信息在分析证书上提供，并且包括对每个批次观察到的所有序列变化的分析.
在GISAID引入的命名系统（全球共享所有流感数据的倡议），SARS-COV-2，分离USA / CA / VRLC012 / 2021分配了谱系P.2（B.1.1.28的子谱系）和GISAID Clade Gr使用Phylo到期的全球爆发谱系（Pangolin）工具的分配. SARS-COV-2的完整基因组，分离为USA / CA / VRLC012 / 2021（GISAID：EPI_ISL_1364506）.以下突变存在于临床分离物中（称为HCOV-19 / USA / CA-STANFORD-04_S01 / 2021）：SPIKE D614G，SPIKE E484K，尖峰V1176F，N（核衣壳蛋白）G204R，N M234I，N R203K， NSP3（非结构蛋白3）P992L，NSP3 V253A，NSP7（非结构蛋白7）L71F，NSP12（非结构蛋白12）P323L. SARS-COV-2，谱系P.2首先在巴西检测到并标记为感兴趣的变种（VOI）.它被世界卫生组织（世卫组织）标记为Zeta Variant.
每个小瓶含有大约0.1ml的旋转澄清的细胞裂解物和来自感染SARS-COV-2的肺腺癌上皮细胞（Calu-3），分离USA / CA / VRLC012 / 2021.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2021-12-21
2022-04-01
2021-12-21
2019-05-08
2022-04-01
2022-04-01
2022-01-10
2021-12-21
2022-03-31
2021-12-21
2022-04-01
2022-04-01
2022-04-01
2024-04-27